Foxp3 regulatory T cells

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

By Targets:	Nuclear Factor of activated T Cells (NFAT) (1) Antibiotic (3) Apoptosis (4) CDK (3) DNA/RNA Synthesis (3) Endogenous Metabolite (1) Interleukin Related (1) NF-κB (2) PKC (1) Reference Standards (1) ROCK (1) STAT (2) TGF-beta/Smad (3) Topoisomerase (3) Transmembrane Glycoprotein (2)
By Research Areas:	Cancer (10) Infection (2) Inflammation/Immunology (10) Neurological Disease (2)
Oligonucleotides:	Antisense Oligonucleotides (2)

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13624A

Epirubicin hydrochloride Maximum Cited Publications 36 Publications Verification 4'-Epidoxorubicin hydrochloride	DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic	Infection Neurological Disease Inflammation/Immunology Cancer
Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .

HY-13624

Epirubicin Maximum Cited Publications 36 Publications Verification 4'-Epidoxorubicin	DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic	Cancer
Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .

HY-148808

Zelasudil RXC007	ROCK	Cancer
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .

HY-126675A

AS2863619 5+ Cited Publications	CDK STAT	Inflammation/Immunology
AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3 ⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .

HY-P1684

Peptide P60 1 Publications Verification Foxp3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a *FOXP3* inhibitor. Peptide P60 reduces the nuclear translocation of *FOXP3* and impairs *FOXP3*-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 ⁺CD25 ⁺Foxp3 ⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .

HY-159692

AZD8701 IONIS-1063734	TGF-beta/Smad	Inflammation/Immunology Cancer
AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting *FOXP3* in regulatory T cells (Tregs), with a human IC₅₀ of 65.2 nM. AZD8701 binds to intronic sites of all *FOXP3* pre-mRNA isoforms and mediates dose-dependent *FOXP3* knockdown via free uptake. AZD8701 can be used in cancer-related research .

HY-126675

AS2863619 free base 5+ Cited Publications	CDK STAT	Inflammation/Immunology
AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3 ⁺ regulatory T (T_reg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC₅₀s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .

HY-13624AR

Epirubicin hydrochloride (Standard) 4'-Epidoxorubicin hydrochloride (Standard)	Reference Standards DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic	Cancer
Epirubicin (hydrochloride) (Standard) is the analytical standard of Epirubicin (hydrochloride). This product is intended for research and analytical applications. Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .

HY-W060417

iST2-1	Interleukin Related	Inflammation/Immunology Cancer
iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC₅₀ value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 ⁺ and CD8 ⁺ T cells, increases regulatory T cell populations, reduces IFN-γ ⁺CD4 ⁺ T cell populations, increases Foxp3 ⁺CD4 ⁺ regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .

HY-159692A

AZD8701 sodium IONIS-1063734 sodium	TGF-beta/Smad	Inflammation/Immunology Cancer
AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting *FOXP3* in regulatory T cells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer .

HY-15091

Anisperimus LF-150195	Endogenous Metabolite	Neurological Disease
Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced T cell death. Anisperimus enhances the sensitivity of T cells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 T cells, thereby preventing central nervous system autoimmunity .

HY-P991824

Anti-Mouse CD4 Antibody (YTS 177)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 ⁺ Foxp3- T cells and Foxp3 ⁺ regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .

HY-10540

Sotrastaurin acetate AEB071 acetate	PKC NF-κB	Inflammation/Immunology
Sotrastaurin (AEB071) acetate is a selective, orally active PKC inhibitor. Sotrastaurin acetate inactivates NF-κB by inhibiting PKC α, β, θ, γ subtypes, thereby reducing the transcription levels of immune response-related genes. Sotrastaurin acetate effectively inhibits alloreactive T cell proliferation, conventional T cell activation, as well as the production of pro-inflammatory cytokines and B lymphocytes. Sotrastaurin acetate also maintains the functional and phenotypic stability of regulatory T cells, enhances *Foxp3* expression and restores the balance of helper T lymphocytes. Sotrastaurin acetate can prolong the survival time of allografts, and alleviate inflammatory responses and myasthenic symptoms by reducing anti-AChR antibody levels. Sotrastaurin acetate is widely used in studies related to kidney transplantation, psoriasis and myasthenia gravis .

HY-P992361

HB0030	Transmembrane Glycoprotein	Cancer
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 ⁺ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .

HY-126675G

AS2863619	CDK TGF-beta/Smad Apoptosis	Inflammation/Immunology
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce *FOXP3* expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

Cat. No.	Product Name	Type

HY-126675G

AS2863619	Fluorescent Dyes
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce *FOXP3* expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

AS2863619

Fluorescent Dyes

AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

Cat. No.	Product Name	Type

HY-126675G

AS2863619	Biochemical Assay Reagents
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce *FOXP3* expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

AS2863619

Biochemical Assay Reagents

AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

Cat. No.	Product Name	Target	Research Area

HY-P1684

Peptide P60 1 Publications Verification Foxp3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a *FOXP3* inhibitor. Peptide P60 reduces the nuclear translocation of *FOXP3* and impairs *FOXP3*-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 ⁺CD25 ⁺Foxp3 ⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .

HY-P2114

IT9302	Peptides	Cancer
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991824

Anti-Mouse CD4 Antibody (YTS 177)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 ⁺ Foxp3- T cells and Foxp3 ⁺ regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .

HY-P992361

HB0030	Transmembrane Glycoprotein	Cancer
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 ⁺ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .

Cat. No.	Product Name		Classification

HY-159692

AZD8701 IONIS-1063734		Antisense Oligonucleotides
AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting *FOXP3* in regulatory T cells (Tregs), with a human IC₅₀ of 65.2 nM. AZD8701 binds to intronic sites of all *FOXP3* pre-mRNA isoforms and mediates dose-dependent *FOXP3* knockdown via free uptake. AZD8701 can be used in cancer-related research .

HY-159692A

AZD8701 sodium IONIS-1063734 sodium		Antisense Oligonucleotides
AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting *FOXP3* in regulatory T cells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer .

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126675G

AS2863619	CDK TGF-beta/Smad Apoptosis	Inflammation/Immunology
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 ⁺ T cells into regulatory T cells and induce *FOXP3* expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Oligonucleotides

GMP Molecules

Name
Email *

	Sorry, but the email address you supplied was invalid.